Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 16 of 16 for “"VX-809"”.

  1. Physiological and pharmacological characterization of the N1303K mutant CFTR

    … to CFTR modulators including potentiators VX-770 and GLPG1837 and correctors VX-809, and VX-661. Methods: Gating behavior and pharmacological responses to CFTR potentiators were assessed using the patch-clamp technique in the excised, inside-out mode. We also examined the effects of …

    missouri Repository record for Physiological and pharmacological characterization of the N1303K mutant CFTR (opens in a new tab)

  2. New treatment options for cystic fibrosis

    … United States Food and Drug Administration, and VX-809 and ataluren, which are still in clinical trial, have been shown to improve patient clinical measures. VX-809 targets the most prevalent CF mutation, F508del, and used in combination with ivacaftor was shown to significantly decrease mean …

    bu Repository record for New treatment options for cystic fibrosis (opens in a new tab)

  3. PHARMACOLOGICAL RESCUE OF NONSENSE MUTATIONS IN CYSTIC FIBROSIS

    … for protein read-through (RT); correctors VX-809 and VX-445 to promote protein maturation and function, PTI-428 to enhance CFTR protein synthesis. We found that the extent of rescue and sensitivity to the various agents is largely dependent on the type of mutation, with the W1282X as the …

    milano Repository record for PHARMACOLOGICAL RESCUE OF NONSENSE MUTATIONS IN CYSTIC FIBROSIS (opens in a new tab)

  4. Investigation of a Selective Transglutaminase 2 Antagonist as a Novel Therapeutic Agent for Cystic Fibrosis

    … HBECs revealed that the use of a CFTR corrector (VX-809) and TG2 specific inhibitor (1-155) in combination, could have a potentially additive therapeutic effect. A more in-depth investigation with IB3 cells, served to further validate these findings. It was demonstrated that the treatment of IB3 …

    aston Download PDF for Investigation of a Selective Transglutaminase 2 Antagonist as a Novel Therapeutic Agent for Cystic Fibrosis (opens in a new tab)

  5. The I507-ATC→ATT silent codon change contributes to the misfolding of ∆F508 CFTR

    … responses to ∆F508 CFTR correctors. I chose VX-809 and C4 based on mechanistic classifications indicating that they target structurally and spatially different ∆F508 folding defects. In Chapter 3, I show that C4 predominantly targets the I507-ATT ∆F508 CFTR and eliminates the …

    uab Repository record for The I507-ATC→ATT silent codon change contributes to the misfolding of ∆F508 CFTR (opens in a new tab)

  6. Insights into the Interactions between CFTR and Small Molecule Modulators

    … investigation of two potentiators: VRT-532 and VX-770, and two correctors VX-809 and C18. We assessed the consequences of interactions with these drugs on CFTR channel activity, ATPase activity and phosphorylation. We demonstrated that VRT-532 binds directly to mutant CFTR to modify its channel …

    toronto-retro Repository record for Insights into the Interactions between CFTR and Small Molecule Modulators (opens in a new tab)

  7. Modulation of Proteostasis for the Efficient Intracellular Transport of the ΔF508 Mutant of Cystic Fibrosis Transmembrane Conductance Regulator

    … clinically studied corrector pharmacochaperone VX-809 led to a high level of correction of ΔF508CFTR, which was much greater than for VX-809 alone. Many candidate genes and drugs that are identified in the current study open the way to the development of the new efficient therapeutic agents for …

    the-open-u Download PDF for Modulation of Proteostasis for the Efficient Intracellular Transport of the ΔF508 Mutant of Cystic Fibrosis Transmembrane Conductance Regulator (opens in a new tab)

  8. Assembly and Trafficking of the Cystic Fibrosis Transmembrane Conductance Regulator and Associated Proteins

    … CFTR correction, using the corrector molecule VX-809, a secondary mutation (I539T), and low temperature conditions. Each individually improved trafficking of ΔF508-CFTR to approximately 10% of wild-type levels. The combination of VX-809 with either low temperature or the I539T mutation …

    uky-thes Repository record for Assembly and Trafficking of the Cystic Fibrosis Transmembrane Conductance Regulator and Associated Proteins (opens in a new tab)

  9. A Structure Based Approach For Defining Ligand Interaction Requirements With Atp-Binding Cassette Proteins

    … amide linker present in the CFTR potentiator VX-770, and the CFTR corrector VX-809, when replaced with a triazole moiety, will maintain chemical and structural features that preserve modulation of CFTR function. To explore the hypothesis, I have solved sub-atomic x-ray crystal structures of …

    uab Repository record for A Structure Based Approach For Defining Ligand Interaction Requirements With Atp-Binding Cassette Proteins (opens in a new tab)

  10. Ribosomal Protein L12 (Rpl12) as a Novel Target in Cystic Fibrosis

    … FDA-approved corrector molecule, Lumacaftor (VX-809). In addition, the use of Rpl12 suppression together with VX-809 improves F508del biogenesis to a degree predictive of clinical benefit in patients. We also elucidate the mechanism by which Rpl12 influences mutant CFTR maturation. Ribosome …

    uab Repository record for Ribosomal Protein L12 (Rpl12) as a Novel Target in Cystic Fibrosis (opens in a new tab)

  11. Flowable Approach for the Formation of Biomaterial Sheets

    … Fibrosis Trans –Regulator corrector, lumacaftor (VX – 809). The second microfluidic strategy allowed the continuous preparation, and processing of meter – long, roll – to – roll processed biomaterial sheets with control over thickness, morphology, and elastic properties. 3D structures with …

    toronto-retro Repository record for Flowable Approach for the Formation of Biomaterial Sheets (opens in a new tab)

  12. Vectorized peptidic Inhibitors to rescue F508del-CFTR in Cystic Fibrosis

    … in a phase 2 trial. Combined administration of VX-809 as “corrector” that acts as a chemical chaperone to assist F508del-CFTR folding and Kalydeco (VX-770) as “potentiator” that enhances CFTR activity showed an improvement of lung function (FEV1) by >10 % for 25 % of patients homozygous for …

    fu-berlin Repository record for Vectorized peptidic Inhibitors to rescue F508del-CFTR in Cystic Fibrosis (opens in a new tab)

  13. Novel Approaches To Enhance Translational Readthrough Efficacy For Cystic Fibrosis Nonsense Mutations

    … enhanced by addition of a CFTR corrector, VX-809, to augment CFTR processing and folding in addition to a CFTR potentiator, VX-770, to enhance channel function. To ultimately evaluate the agents in vivo, we generated and chacterized a novel NMD sensitive CFTR-G542X, homozygous rat model …

    uab Repository record for Novel Approaches To Enhance Translational Readthrough Efficacy For Cystic Fibrosis Nonsense Mutations (opens in a new tab)

  14. GANGLIOSIDE GM1 AS ADJUVANT FOR ORKAMBI® THERAPY TO RESTORE PLASMA MEMBRANE STABILITY AND FUNCTION OF F508DEL-CFTR

    … a corrector of the CFTR folding (lumacaftor or VX-809) and a potentiator of the channel activity (ivacaftor or VX-770) called Orkambi®, was approved for CF patients homozygous for the deletion of phenylalanine at position 508 (F508del), the most common CF-causing mutation. Unfortunately, …

    milano Repository record for GANGLIOSIDE GM1 AS ADJUVANT FOR ORKAMBI® THERAPY TO RESTORE PLASMA MEMBRANE STABILITY AND FUNCTION OF F508DEL-CFTR (opens in a new tab)

  15. Nonsense Suppression In A Cftr Mouse Model And Analysis Of Animo Acids Inserted At Cftr Premature Termination Codons In Mammalian Cells

    … variant function. The CFTR corrector lumacaftor (VX-809) improved the processing and the CFTR potentiator ivacaftor (VX-770) enhanced the activity of CFTR in some of these variants. In addition, the combination of nonsense suppression drug G418, lumacaftor and ivacaftor showed synergistic …

    uab Repository record for Nonsense Suppression In A Cftr Mouse Model And Analysis Of Animo Acids Inserted At Cftr Premature Termination Codons In Mammalian Cells (opens in a new tab)

  16. LIPID-BASED APPROACHES TO OPTIMIZE THE EFFECTIVENESS OF INNOVATIVE DRUG MODULATORS IN CYSTIC FIBROSIS

    … combination Kaftrio (comprising two correctors, VX-661, VX-445, and a potentiator, VX-770) as a pharmacological intervention for CF patients who have at least one F508del mutation in the CFTR gene. In my PhD project, I explored the impact of Kaftrio on the lipid composition of bronchial …

    milano Repository record for LIPID-BASED APPROACHES TO OPTIMIZE THE EFFECTIVENESS OF INNOVATIVE DRUG MODULATORS IN CYSTIC FIBROSIS (opens in a new tab)